Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul;19(2):149-59.
doi: 10.1007/s10911-014-9320-1. Epub 2014 Jun 10.

CSF-1R signaling in health and disease: a focus on the mammary gland

Affiliations
Review

CSF-1R signaling in health and disease: a focus on the mammary gland

Amy Renee Sullivan et al. J Mammary Gland Biol Neoplasia. 2014 Jul.

Abstract

Colony-stimulating factor-1 (CSF-1), also known as macrophage-colony stimulating factor (M-CSF), is the primary growth factor regulating survival, proliferation and differentiation of macrophages. It is also a potent chemokine for macrophages and monocytes. Signaling via the CSF-1 receptor (CSF-1R) is necessary for the production of almost all tissue resident macrophage populations and these macrophages participate, via trophic mechanisms, in the normal development and homeostasis of tissues and organs in which they reside, including the mammary gland. The drawback of this close interaction between macrophages and parenchymal cells is that dysregulation of macrophage trophic functions assists in the development and progression of many cancers, including breast cancer. Furthermore, tumour cells secrete CSF-1 to attract more macrophages to the tumour microenvironment where CSF-1R signaling frequently drives the behaviour of these tumour-associated macrophages (TAMs) to promote tumour progression and metastasis. Evidence is mounting that treated tumours secrete more CSF-1 and the increased recruitment of TAMs limits treatment efficacy. Thus, therapeutic targeting of the CSF-1R to inhibit TAM function is likely to enhance tumour response and improve patient outcomes in the treatment of cancer, including breast cancer.

PubMed Disclaimer

References

    1. Immunity. 2013 Apr 18;38(4):792-804 - PubMed
    1. Immunity. 2013 Jan 24;38(1):79-91 - PubMed
    1. Cancer Res. 2006 Dec 1;66(23):11238-46 - PubMed
    1. Vasc Cell. 2013 Dec 06;5(1):20 - PubMed
    1. J Immunol. 2010 Jan 15;184(2):702-12 - PubMed

MeSH terms

Substances

LinkOut - more resources